Dr. Jesus Soberino is an oncologist at Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO). He specializes in breast cancer and melanoma. Dr. Soberino has led many phase 1–3 clinical trials. His work has helped approve important drugs, including CDK4/6 inhibitors for metastatic breast cancer and immunotherapies for melanoma.
His areas of expertise include endocrine therapy, managing hormone resistance, and developing new immunotherapies. Dr. Soberino is known for his patient-centered care. He actively collaborates in research to improve cancer treatment. He is accredited by VHIO and is a key member of the Breast Cancer and Melanoma Units.
Dr. Francesc Graus is a neurologist with expertise in paraneoplastic neurological syndromes, gliomas, and primary brain lymphomas. He established the first strict diagnostic criteria for paraneoplastic syndromes. He also identified important antibodies that are now used in diagnosis. His research showed the link between tumors and autoimmune neurological attacks.
Dr. Graus earned his MD and PhD from Universitat Autònoma de Barcelona. He completed his neurology residency in Barcelona and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. He is an Emeritus investigator at IDIBAPS. He founded and served as president of the European Association of Neuro-Oncology. He is also the former chief of neurology at Hospital Clinic Barcelona.
Experience
2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL
2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer
2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital
2020 - 2021 Yüzüncü Yıl University Faculty of Medicine
2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.
2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department
2018 - 2021 Yüzüncü Yıl University Faculty of Medicine
2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital
2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant
2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist
2012 - 2015 Suleiman the Magnificent Training and Research Hospital,
2008 - 2012 Haseki Training and Research Hospital
2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.
Education
2018
İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji
2018
İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji
2012
İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları
2012
İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları
2007
Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi
Dr. Selime Aydogdu is a specialist in pediatric hematology and oncology. She is known for her work in improving early cancer detection in children. Dr. Aydogdu has given many presentations and led discussions on recognizing early cancer symptoms. Her efforts have raised awareness in her field.
Her work has helped achieve better diagnostic results and higher survival rates for children. Dr. Aydogdu is dedicated to education and advocacy. She is a respected member of the pediatric oncology community.
Professional experience:
04.2009 – 04.2013: Resident in the Department for Radiation Oncology, Klinikum Offenbach
05.2013 – 12. 2015: Senior physician in the Department for Radiation Oncology, Klinikum Offenbach
Education
09 / 2004 – 07 / 2006 Movie Director School, ANT1 Movie School Athens, Greece, Degree “Television Director”, grade point average: B
09 / 2006 – 08 / 2008 Medical School, Semmelweis University Budapest, Hungary, Medical preliminary examination (Physikum), grade point average: A
10 / 2008 – 05 / 2013 Medical School, Albert-Ludwigs-Universität Freiburg, Germany, State examination in medicine, grade point average: A
02/ 2009 – 02/2012 Institute of Pharamcology and Toxicology I, Albert-Ludwigs-Universität Freiburg, Germany, Doctoral thesis, grade: summa cum laude
05 / 2018 Basic and advanced course in German drug law and GCP, Clinical Trials Unit, Medical Center - University of Freiburg
01 / 2019 Board certification: Radiotherapy and Radiation Oncology
03 / 2020 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Habilitation (Postdoctoral lecture qualification)
09 / 21 – 08 / 23 MHBA, Friedrich Alexander University, Nuernberg, Germany
07 / 2022 Completion of ISO 9001:2015 training, Nicosia, Cyprus
Professional Career
09 / 2013 – 01 / 2019 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Residency
07 / 2017 – 07 / 2020 Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Clinician Scientist
Since 06 / 2019 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Consultant
01 / 2021 – 12 / 2022 Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Advanced Clinician Scientist
01 / 2021 – 12 / 2021 Head of the section “Interventional Radiation Oncology”, Medical Center University of Freiburg, Department of Radiation Oncology, Germany
Since 01 / 2022 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Prostate cancer research group leader
Since 01 / 2022 German Medical Institute, Limassol, Cyprus, Vice Medical Director
Professional Memberships and Distinctions
2010 Sanofi-Aventis poster prize, Annual meeting of the German Society of Pharmacology and Toxicology 2010, Mainz, Germany
2017 Poster prize, Annual meeting of the German Society of Radiation Oncology (DEGRO) 2017, Berlin, Germany
2019 Poster prize, Uro-Oncological Symposium 2019, Magdeburg, Germany
2020 Invited member of the German expert panel for prostate cancer of the German Society of Radiation Oncology (DEGRO)
2020 Herman-Holthusen Award, German Society of Radiation Oncology (DEGRO)
2021 Invited member of the ESTRO-ACROP guideline committee for prostate cancer
2021 Best Abstract, EMUC congress 2021, Athens, Greece
2023 Annual ARO study price for the HypoFocal-SBRT study from the German Cancer Foundation
2023 Invited member of the ESTRO focus group “Urology”
Dr. Francesc Cobo Valien graduated from the Faculty of Medicine of the University of Barcelona in 1990.
He received his specialization in oncohematology at the Hospital Clínic de Barcelona in 1995. He combined medical practice and research activities in the period 1996-2002.
He received his Doctor of Medicine degree from the University of Barcelona in 2002.
Dr. Kobo continues his research and has been awarded grants:
•Interdepartmental Commission for Innovation of the Generalitat de Catalunya
•Scholarship Fund Universitaria Agustí Pedro i Pons
•Farreras Valentí & Schering Plough School of Hematology Scholarship
•Award for the best report at the Council of the Spanish Hematology Association
•Grant from the Catalan Society of Hematology
Specialization:
•Lymphoma
•Acute leukemia
•Chronic leukemia
•Autoimmune pancytopenia
Dr. Balaña received her medical degree from the Central University of Barcelona and completed her residency in medical oncology at one of the best public hospitals in Spain, Vall d'Hebrón Hospital.
She was a leading specialist in the treatment of brain tumors at the Institute of Oncology of Catalonia, a founding member and current president of the Spanish Neuro oncology Research Group (GEINO), and a member of the scientific committee of the European Association for Neuro-Oncology.
He is the recipient of prestigious research grants in the field of brain tumors.
Dr. Balaña is also a member of the European Society of Medical Oncology and the author of modern European protocols for the treatment of brain tumors, as well as the protocols of the Spanish Society of Medical Oncology (SEOM).
Dr. Balaña has published over 400 articles, books and scientific papers at national and international conferences.
He is the author of articles in prestigious scientific publications such as:
Lancet Oncology;
Nature Reviews in Clinical Oncology;
Clinical Cancer Research and others.
Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.
Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.
Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology
Education:
Professional Experience:
Clinical Trials, Courses, Certifications:
Clinical Trials:
Courses:
Certifications:
Memberships:
Education
Experience
Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).
He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.
Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.
Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.
Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).
Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).
Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.
He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.
Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.
EDUCATION AND ADVANCED TRAINING COURSES
Today, Professor Rifaat Safadi is an outstanding specialist in the field of liver disease treatment, a member of the committee for the development of the somatic cell transplant center and the head of the liver disease unit at Hadassah Medical Center. The professor is a member of several international associations for the study of the liver and is the author of numerous articles in his specialty. Professor Safadi is a member of the editorial board of the scientific medical journal Clinical Science.
Rifaat Safadi is a laureate of many scientific awards. In particular, he has been repeatedly awarded the Hadassah Prize for studying the process of immune modulation of liver fibrosis using mRNA. For achievements in the same field, the professor received the Sharon Donsky and the Israeli Association of Gastroenterology and Hepatology awards.
Dr. Francesc Bosch is an expert in Chronic Lymphocytic Leukemia (CLL) and lymphomas. He leads research in the molecular causes and new treatments for CLL and other lymphoproliferative disorders.
He has published over 100 articles in leading journals, including The New England Journal of Medicine and Nature Medicine. Dr. Bosch oversees more than 80 clinical studies, from phase 1 to phase 3, and plays a key role in developing new drugs.
He is the Head of Hematology at Vall d’Hebron University Hospital and IOB Institute of Oncology. He also serves as president of GELLC and is a professor of hematology. His work has improved diagnosis and treatment for blood diseases.
Dr. Ana Oaknin is a Medical Oncologist with expertise in angiogenesis, DNA repair, and immunology. She focuses on gynecological cancers. Dr. Oaknin earned her medical degree and MD in Medical Oncology from Complutense University of Madrid. She also holds a PhD from Universidad Autonoma de Barcelona.
Dr. Oaknin is Co-Chair of the GEICO Group. She is a faculty member for the Gyn-Track in the European Society of Medical Oncology. She represents Spain in the GOG and GCIG committees. Dr. Oaknin is an active member of ASCO, ESMO, and SEOM. She has published over 100 scientific articles and presentations. She also leads several clinical trials in ovarian, cervical, and endometrial cancer.